INA-RESPOND Publication Policy

1. Introduction

The Indonesian Infectious Disease Research Partnership (INA-RESPOND) is a collaborative initiative between the National Institute of Health Research and Development (NIHRD) and the National Institute of Allergy and Infectious Disease (NIAID), along with 7 Schools of Medicine and 9 Hospitals (University of Indonesia/Dr Cipto Mangunkusumo Hospital, Sulianti Saroso Infectious Disease Hospital, Persahabatan Hospital, Padjadjajaran University/Dr Hasan Sadikin Hospital, University of Diponogoro/Dr Kariadi Hospital, University of Gadjah Mada/Dr Sadjito Hospital, University of Airlangga/Dr Soetomo Hospital, University of Udayana/Sanglah Hospital, University of Hasanuddin/Dr Wahidin Sudirohusodo Hospital) in 7 cities in Indonesia that is formed to promote and conduct high-quality infectious disease clinical research in Indonesia.
The Indonesian Infectious Disease Research Partnership (INA-RESPOND) is the sole owner of data generated from every network study conducted at the network sites. The primary results of each study conducted by INA-RESPOND are expected to be shared with the scientific community and stakeholders through presentations at open scientific meetings and peer-reviewed publications in scientific journals or books. This has also been explicitly stated as one of the key performance indicators for the success of INA-RESPOND in the strategic plan. Furthermore, it is a responsibility to volunteers who are willing to participate in scientific research to disseminate research results.

2. Purpose

To ensure that researchers from the INA-RESPOND are equitably acknowledged and their contributions are fairly represented.

3. Definitions

  1. Publications: The outcome of research that is disseminated in scientific meetings (orally or in form of posters) or in writings such as in proceedings, peer-reviewed journal, or books.
  2. Authorship: The intellectual participation in conceiving, executing, or interpreting at least part of the research in the author’s field of expertise, sufficient for the author to take public responsibility for that output. The criteria for authorship adhere to internationally recognized standards and are limited to those making major contributions to the study and subsequent manuscript preparation.
  3. The sequence of authorship sorted based on the contributions given (descending)
    a. First author: the Principal Investigator (PI) that contributed the most and performed the majority of work in terms of study design, data collection, analysis, and writing of the manuscript.
    b. Second author and other co-authors: authors involved in the research process until publication.
    c. Multiple first authors: these two authors contribute equally both to the research and to the writing of the manuscript. (Usually these authors will have a star by their names with a footnote to explain their contributions).
    d. Second to last author: usually the second most senior person whose responsibilities are similar to the senior author in supervising the study and the writing of the manuscript.
    e. Last author/senior author: the senior author who can be the PI of the study.
    f. Corresponding author: the author who takes part in manuscript writing and submits it to a journal, corresponds with the journal editors, responds to queries from reviewers, and provides explanations from the authors.
    g. Group author: a strategy used when author numbers are limited. In this case, the name of the group is used instead, e.g. Writing Group of INA-RESPOND or On Behalf of INA-RESPOND.
  4. Acknowledgment: a section at the end of the manuscript to acknowledge those who have supported the research.
  5. Documentation of National Clinical Trial (NCT) Number (if applicable). INA-RESPOND clinical trials must be registered with the ClinicalTrials.gov web-based protocol registration system. A unique identifier (NCT number) is provided and should be documented in the final manuscript, according to the target journal’s requirements.
  6. Changes to site staff: in instances when study work was completed or substantially conducted by an investigator or staff who are no longer part of the site study team, it is the responsibility of the site PI to determine whether that former team member should be an author or acknowledged in the publication.

4. Publication Process

The PI for a particular study protocol will be responsible for establishing a Manuscript Writing Committee (MWC), which is composed of site investigators and a study statistician. The Network Steering Committee (NSC) should approve the composition of this committee. The MWC is responsible for developing an overall publication strategy. The MWC will develop a plan for the dissemination of the study results, including proposed meetings and seminars for presentations, numbers and content of manuscripts, target journals for submission and selection and sequence of authors. This plan will be submitted to the NSC for approval before proceeding with drafting the initial manuscript(s) that detail the primary results of the study. Site PIs within the Network who have specific ideas for a sub-study manuscript derived from the data developed in a particular study are encouraged to submit a brief summary of their concept to the MWC with a copy to the NSC for consideration. The completed manuscript must be submitted to the NSC for final approval.

5. Conflicts or Changes

The NSC will discuss conflicts or changes related to the publication policy. If not resolved, they will be brought to the Governing Board for final decision.

Publication List

  1. Commentary: data sharing in South East Asia. Grue L, Siddiqui S, Limmathurotsakul D, Kamaludi A, Karyana M, Lau CY. BMJ, 2016 Oct 10;355:i5363.
  2. Case report: Weil’s disease with multiple organ failure in a child living in dengue endemic area. Lokida, D., A. Budiman, U. E. Pawitro, M. H. Gasem, M. Karyana, H. Kosasih and S. Siddiqui. BMC Res Notes, 2016. 9(1): p. 407.
  3. Comparison of the Hemagglutination Inhibition Test and IgG ELISA in Categorizing Primary and Secondary Dengue Infections Based on the Plaque Reduction Neutralization Test. Lukman, N., G. Salim, H. Kosasih, N. H. Susanto, I. Parwati, S. Fitri, B. Alisjahbana, S. Widjaja and M. Williams. Biomed Res Int, 2016. 2016: p. 5253842.
  4. The Epidemiology, Virology and Clinical Findings of Dengue Infections in a Cohort of Indonesian Adults in Western Java. Kosasih H, Alisjahbana B, Nurhayati, de Mast Q, Rudiman IF, Widjaja S, Antonjaya U, Novriani H, Susanto NH, Jusuf H, van der Ven A, Beckett CG, Blair PJ, Burgess TH, Williams M, Porter KR. PLoS Negl Trop Dis. 2016 Feb 12;10(2):e0004390.
  5. Detection of group A rotavirus strains circulating among children with acute diarrhea in Indonesia. Nirwati H, Wibawa T, Aman AT, Wahab A, Soenarto Y. Springerplus. 2016 Jan 29;5:97.
  6. Study of viremic profile in febrile specimens of chikungunya in Bandung, Indonesia. Riswari SF, Ma’roef CN, Djauhari H, Kosasih H, Perkasa A, Yudhaputri FA, Artika IM, Williams M, van der Ven A, Myint KS, Alisjahbana B, Ledermann JP, Powers AM, Jaya UA. J Clin Virol. 2016 Jan;74:61-5.
  1. Association of opportunistic infections with HIV-RNA and CD4 cell count in pre arv and arv failure at the care support treatment clinic of sanglah hospital, Bali. Utama, M. S., & Merati, T. P. Association of opportunistic infections with HIV-RNA and CD4 cell count in pre arv and arv failure at the care support treatment clinic of sanglah hospital, Bali. Journal of Epidemiological Research, 2015:2(2), p13.
  2. RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration. Hamilton CD, Swaminathan S, Christopher DJ, Ellner J, Gupta A, Sterling TR, Rolla V, Srinivasan S, Karyana M, Siddiqui S, Stoszek SK, Kim P. Clin Infect Dis. 2015 Oct 15;61Suppl 3:S155-9.
  3. Molecular epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis drugs in Indonesia. Lisdawati V, Puspandari N, Rif’ati L, Soekarno T, M M, K S, Ratnasari L, Izzatun N, Parwati I. BMC Infect Dis. 2015 Aug 22;15:366.
  4. INA-RESPOND: a multi-centre clinical research network in Indonesia. Karyana M, Kosasih H, Samaan G, Tjitra E, Aman AT, Alisjahbana B, Fatmawati, Gasem MH, Arif M, Sudarmono P, Suharto, Merati TP, Lane C, Siswanto, Siddiqui S. Health Res Policy Syst. 2015 Jul 29;13:34.
  5. Cyclosporine A decreases the fluconazole minimum inhibitory concentration of Candida albicans clinical isolates but not biofilm formation and cell growth. Wibawa T, Nurrokhman, Baly I, Daeli PR, Kartasasmita G, Wijayanti N. Trop Biomed. 2015 Mar;32(1):176-82.
  6. Chikungunya Virus Mutation, Indonesia, 2011. Maha MS, Susilarini NK, Hariastuti NI; Subangkit. Emerg Infect Dis. 2015 Feb;21(2):379-81.
  7. Preliminary Study of Herbal Topical Repellent Made of Betel Leaves (Piper betle) and Patchouli Oil (Pogostemon cablin) Mixture Against Yellow Fever Mosquito (Aedes aegypti). Widawati, M., & Riandi, M. U. BIOTROPIA-The Southeast Asian Journal of Tropical Biology, 2015;22(1).
  1. Efficacy of Artemisinin-Naphtoquine and Dihydroartemisinin-Piperaquine for uncomplicated malaria patient at primary health care. Siswantoro, H., Hasugian, A. R., & Tjitra, E. Health Science Journal of Indonesia, 2014 Dec 2;5:100-105.
  2. Antibody response against three Plasmodium falciparum merozoite antigens in Mamuju District, West Sulawesi Province, Indonesia. Sennang N, Rogerson S, Wahyuni S, Yusuf I, Syafruddin D. Malaria Journal. 2014 Sep 25;13:381.
  3. Managing Seasonal Influenza: oseltamivir Treatment Policy in Indonesia? Kosasih H, Bratasena A, Pangesti K, Laras K, Samaan G. Acta Med Indones. 2014 Jan;46(1):58-65.

Assessing Risk For Severe Manifestation Of Dengue Virus Infection: Role Of Enzyme Metalloproteinase 9